Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, shows promise in managing obesity and type 2 diabetes. This bibliometric analysis maps its research landscape, identifying trends, collaborations, and emerging themes to guide future investigations. A structured search of the Scopus database was performed using the keywords "tirzepatide" in titles or abstracts, limited to English-language original articles. A total of 446 documents were retrieved. Bibliometric analysis was conducted using VOSviewer (v1.6.19), Biblioshiny (Rstudio plugin), and CiteSpace (v6.2.R6) to visualize co-authorship, keyword co-occurrence, citation patterns, and thematic evolution. Tirzepatide publications peaked in 2024 (n = 163), with the USA leading (n = 243, 10,076 citations). Key authors included Urva, S. and Haupt, A. Three thematic clusters emerged: pharmacological mechanisms, clinical outcomes, and study design. Emerging topics included weight reduction, pharmacovigilance, and cost-effectiveness. Co-citation analysis identified four author clusters, with Frias J.P. (TLS = 13,605) most influential. Journals like Diabetes, Obesity and Metabolism dominated. Thematic evolution showed shifts toward real-world evidence and metabolic dysfunction-associated steatotic liver disease, reflecting broadening research scope. Tirzepatide research is growing globally with diverse collaborations, informing future therapeutic strategies and highlighting gaps in long-term safety, accessibility, and cost-effectiveness.